Two Sigma Advisers’s OncoMed Pharmaceuticals, Inc. OMED Stock Holding History

Two Sigma Advisers’s Portfolio OMED Stock Details OMED Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-11,300	Closed	-$12K	–	2546
2019 Q1	$12K	Sell	11,300 -9,100	-45%	-$7.41K	﹤0.01%	2265
2018 Q4	$15K	Sell	20,400 -500	-2%	-$753	﹤0.01%	2321
2018 Q3	$44K	Sell	20,900 -1,400	-6%	-$3.35K	﹤0.01%	2181
2018 Q2	$52K	Buy	22,300 +12,300	+123%	+$35.8K	﹤0.01%	2307
2018 Q1	$32K	Sell	10,000 -200	-2%	-$551	﹤0.01%	2268
2017 Q4	$42K	Buy	+10,200	New	+$44.4K	﹤0.01%	2202
2017 Q3	–	Sell	-11,800	Closed	-$39K	–	2471
2017 Q2	$39K	Buy	+11,800	New	+$49K	﹤0.01%	2220

Two Sigma Advisers's OMED Position: Q2 2019 in Review

Two Sigma Advisers sold out of OncoMed Pharmaceuticals, Inc. (OMED) in Q2 2019, closing a stake of 11,300 shares — an estimated $12K sold.

Two Sigma Advisers first reported a position in OMED in Q2 2017 and held it in 7 quarters. The position peaked at $52K in Q2 2018. 0 funds tracked by Wall St. Rank hold OMED as of Q2 2019.

Two Sigma Advisers reported no remaining OncoMed Pharmaceuticals, Inc. position as of Q2 2019 after selling out during the quarter.
Two Sigma Advisers sold 11,300 OncoMed Pharmaceuticals, Inc. shares in Q2 2019, an estimated $12K.
Two Sigma Advisers first reported a position in OncoMed Pharmaceuticals, Inc. in Q2 2017 and held it in 7 quarters.
Two Sigma Advisers's OncoMed Pharmaceuticals, Inc. position peaked at $52K in Q2 2018.
0 funds tracked by Wall St. Rank held OncoMed Pharmaceuticals, Inc. as of Q2 2019.

Based on Two Sigma Advisers's 13F filing for Q2 2019, filed 14 Aug 2019.